1246525-60-9
1246525-60-9 结构式
基本信息
RORΑ/Γ激动剂(SR1078)
N-[4-[2,2,2-三氟-1-羟基-1-(三氟甲基)乙基]苯基]-4-(三氟甲基)苯甲酰胺
SR 1078
SR-1078
SR 1078 USP/EP/BP
SR1078
SR 1078
SR-1078
SR1078,N-[4-(2,2,2-TRIFLUORO-1-HYDROXY-1-TRIFLUOROMETHYL-ETHYL)-PHENYL]-4-TRIFLU
N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxy-2-propanyl)phenyl]-4-(trifluoromethyl)benzamide
N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide
Benzamide, N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)-
SR1078,N-[4-(2,2,2-Trifluoro-1-hydroxy-1-trifluoroMethyl-ethyl)-phenyl]-4-trifluoroMethyl-benzaMide
N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide SR1078
物理化学性质
制备方法
722-92-9
329-15-7
1246525-60-9
在氩气保护下，向含有4-(六氟-2-羟基异丙基)苯胺（1.5M THF溶液，128μL，0.193mmol）的二氯甲烷（275μL）溶液中依次加入N,N-二异丙基乙胺（37μL，0.212mmol）和4-三氟甲基苯甲酰氯（30μL，0.193mmol）。反应混合物在室温下搅拌8小时后，减压浓缩。粗产物直接通过硅胶柱色谱法纯化，洗脱剂为已烷/乙酸乙酯（8/2），得到59mg（产率71%）的N-[4-[2,2,2-三氟-1-羟基-1-(三氟甲基)乙基]苯基]-4-(三氟甲基)苯甲酰胺（SR1078），为白色粉末。红外光谱（IR, cm-1）：3404, 3214, 1671, 1602, 1529, 1417, 1322, 1272, 1206, 1190, 1176, 1138, 1117, 1065, 1016, 973, 964, 948, 902, 857, 830, 765, 752, 737, 704, 692。1H NMR（400 MHz, (CD3)2SO）：δ 7.68（d, J = 8.2 Hz, 2H），7.89-7.96（m, 4H），8.16（d, J = 8.2 Hz, 2H），8.66（s, 1H），10.67（s, 1H）。13C NMR（100 MHz, (CD3)2SO）：δ 120.12（2C），125.4（q, J = 4.0 Hz, 2C），125.8, 123.3（2C），128.7（2C），131.5（q, J = 31.9 Hz, 1C），138.4, 140.4, 164.7。质谱（ES-）：m/z = 430（C17H10F9NO2-H+）。熔点：169℃。
参考文献：
[1] Patent: WO2011/115892, 2011, A1. Location in patent: Page/Page column 5; 87; 88
[2] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 24, p. 6604 - 6609
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/09/19 | S5775 | SR1078 SR1078 | 1246525-60-9 | 5mg | 876.57元 |
| 2025/09/19 | S5775 | SR1078 | 1246525-60-9 | 10mM (1mL in DMSO) | 1040.13元 |
| 2025/09/19 | S5775 | SR1078 SR1078 | 1246525-60-9 | 25mg | 2923.95元 |
常见问题列表
| Target | Value |
|
RORα
() | |
|
RORγ
() |
SR1078 is a synthetic RORα/RORγ ligand. SR1078 modulates the conformation of RORγ in a biochemical assay and activates RORα and RORγ driven transcription. Furthermore, SR1078 stimulates expression of endogenous ROR target genes in HepG2 cells that express both RORα and RORγ. In a cell-based chimeric receptor Gal4 DNA-binding domain-NR ligand binding domain cotransfection assay, SR1078 significantly inhibits the constitutive transactivation activity of RORα and RORγ, but has no effect on the activity of FXR, LXRα and LXRβ. In a RORα cotransfection assay, treatment of cells with SR1078 (10 μM) results in a significant increase in transcription. Similarly, in the RORγ cotransfection assay, SR1078 treatment results in a stimulation of RORγ-dependent transcription activity.
SR1078 (2-10 μM; 24 hours) shows a dose-dependent increase in expression of A2BP1, CYP19A1, NLGN1, and IPTR1 in SH-SY5Y cells. EC50’s are in the range of 3-5 μM.
The pharmacokinetic properties of SR1078 are examined in mice and noted significant exposure. Plasma concentrations reach 3.6 μM 1h after a 10 mg/kg i.p. injection of SR1078 and sustained levels of above 800 nM even 8h after the single injection. These levels are sufficient to perform a proof-of-principle experiment to determine if SR1078 treatment would stimulate ROR target gene expression in an animal model. Mice are treated with SR1078 (10 mg/kg; i.p.) and 2h after the injection the livers are harvested and mRNA purified for assessment of
G6Pase
and
FGF21
gene expression.T he expression of both
FGF21
and
G6Pase
is significantly stimulated by SR1078 treatment vs. vehicle control.
SR1078 (10 mg/kg; i.p.) shows a significant 25% reduction in repetitive grooming behavior in the BTBR mice.